Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amsterdam Spondyloarthritis cohort
NL-OMON47286Phase 4Not yet recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Sep 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of infliximab, etanercept, adalimumab, golimumab, certolizumab pegol and 1 more in spondyloarthritis (SpA), axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA) and 2 more (2 cohorts), sponsored by Vrije University Medical Center. Primary endpoints: Disease activity change, Adverse events and 7 more. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
03
Conditions
spondyloarthritis (SpA)axial spondyloarthritis (axSpA)non-radiographic axial spondyloarthritis (nr-axSpA)ankylosing spondylitis (AS)peripheral spondyloarthritis (pSpA)
Beyond the preview
Go deeper on NL-OMON47286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47286.